Blood tests to predict lung cancer return after surgery
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether two blood tests, CEA and ctDNA (also called MRD), can help predict if lung cancer will come back after surgery. If these tests are accurate, doctors might be able to monitor patients more closely and catch a recurrence earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a malignant lung tumor that was removed by surgery.
- Your blood test for CEA before surgery was higher than 5 mg/l.
- You had a blood test for MRD (ctDNA) done before your surgery.
- You have had at least two follow-up blood tests for CEA and MRD within two years after your surgery.
- You have not had any other cancer in the last five years, and this is not a secondary lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
This study checks whether a simple blood test (called ctDNA) can predict if liver cancer will come back after surgery. It compares the blood test to a standard lab result from the removed tumor, which may help doctors plan better follow-up care.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
Hear when a new Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.